The efficacy of alefacept in the treatment of chronic plaque psoriasis. J Cutan Med Surg 2004 Dec;8 Suppl 2:3-9
Date
01/26/2005Pubmed ID
15668749DOI
10.1007/s10227-004-9502-3Scopus ID
2-s2.0-13644250766 (requires institutional sign-in at Scopus site) 4 CitationsAbstract
With the completion of several phase 2 and phase 3 clinical studies, the efficacy and tolerability of alefacept in patients with chronic plaque psoriasis is now well studied. The majority of patients treated with a single course of intravenous or intramuscular alefacept experienced a clinically meaningful response. The efficacy of alefacept correlated with its ability to selectively target and reduce the number of pathogenic memory T cells. A second course of alefacept resulted in further clinical improvement, with increasing response rates and prolonged response duration following treatment cessation. Subpopulation analyses demonstrated that alefacept is effective in a broad spectrum of patients with psoriasis, regardless of disease severity, history of and response to prior antipsoriatic treatment, or whether patients are refractory to or have contraindications to other systemic psoriasis therapies or phototherapy.
Author List
Gordon KB, Valentine JAuthor
Kenneth Brian Gordon MD Chair, Professor in the Dermatology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdolescentAdult
Aged
Aged, 80 and over
Chronic Disease
Double-Blind Method
Female
Humans
Male
Middle Aged
Multicenter Studies as Topic
Psoriasis
Randomized Controlled Trials as Topic
Recombinant Fusion Proteins
